Current and future trends in tuberculosis

Tuberculosis has shown higher rate of mortality than HIV because bacteria undergoes genetic mutation and forms resistance to present effective antibiotics. In 2013 WHO detected multiple drug resistance of 480,000 cases. There has been a great success in effective techniques in preventive care, infection care and treatment. Annual mortality rate has decreased since 1990. A sequence of international clinical trials by The British Medical council research, a four drug regimen was given for use in recently diagnosed tuberculosis patient. In latest research techniques of vaccines or new drug development are used to reduce risk in latently infected people. Despite of increasing funds in tuberculosis only 20 clinical trials of drugs and 12 vaccines are conducted.

  • Current global distribution in TB
  • Antibiotic resistance
  • New TB bio markers
  • Drugs under trials

Related Conference of Current and future trends in tuberculosis

February 24-25, 2020

7th International Congress on Infectious Diseases

Berlin, Germany
April 27-28, 2020

7th Global Congress on Rare Diseases & Orphan Drug

Istanbul, Turkey
June 09-10, 2020

10th European Epidemiology and Public Health Congress

Istanbul, Turkey
July 22-23, 2020

10th World Congress on Rare Diseases and Orphan Drugs

Barcelona, Spain
August 19-20, 2020

European Summit on HIV, STD and STIs

Milan, Italy
September 28-29, 2020

13th Global Infections Conference

September 28-29, 2020

World Congress on Infectious Diseases and Rare Diseases

Osaka, Japan
October 5-6, 2020

12th Euro-Global Conference on Infectious Diseases

Vienna, Austria

Current and future trends in tuberculosis Conference Speakers

Recommended Sessions

Related Journals

Are you interested in